Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04810611
Title Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

myelodysplastic syndrome

Therapies

NIS793

Sabatolimab

Canakinumab + Sabatolimab

NIS793 + Sabatolimab

Canakinumab

Age Groups: senior | adult
Covered Countries USA | ITA | ESP


No variant requirements are available.